(Total Views: 295)
Posted On: 06/11/2020 4:26:47 PM
Post# of 112
NetworkNewsBreaks – Cannabis Global, Inc. (MCTC) Adds Cannabinol (“CBN”) to R&D Effort for Project Varin
Cannabis Global (OTC: MCTC), a cannabinoid and hemp extract science-forward company developing infusion and delivery technologies, today announced the expansion of its Project Varin research and development effort to include Cannabinol (“CBN”) under the umbrella of patent pending polymeric nanoparticle and nanofiber technologies developed for Tetrahydrocannabivarin (“THC-V”). According to the update, the first stage of Project Varin produced high load particles of pure THC-V, allowing Cannabis Global to now move into production of commercial quantities. CBN has been added to the production protocol as part of this second phase. “The addition of CBN to the Project Varin production schedule is an important test of our internally developed technologies,” Arman Tabatabaei, CEO of Cannabis Global, said in the news release. “We believe the production parameters developed for THC-V will apply to CBN and other manufactured cannabinoids and we will be testing this premise on our currently scheduled manufacturing run. This will be an important test of the flexibility of our manufacturing process and if successful should allow us low cost leadership over a variety of rare cannabinoids.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Cannabis Global (OTC: MCTC), a cannabinoid and hemp extract science-forward company developing infusion and delivery technologies, today announced the expansion of its Project Varin research and development effort to include Cannabinol (“CBN”) under the umbrella of patent pending polymeric nanoparticle and nanofiber technologies developed for Tetrahydrocannabivarin (“THC-V”). According to the update, the first stage of Project Varin produced high load particles of pure THC-V, allowing Cannabis Global to now move into production of commercial quantities. CBN has been added to the production protocol as part of this second phase. “The addition of CBN to the Project Varin production schedule is an important test of our internally developed technologies,” Arman Tabatabaei, CEO of Cannabis Global, said in the news release. “We believe the production parameters developed for THC-V will apply to CBN and other manufactured cannabinoids and we will be testing this premise on our currently scheduled manufacturing run. This will be an important test of the flexibility of our manufacturing process and if successful should allow us low cost leadership over a variety of rare cannabinoids.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
